Background: Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of pyroglutamate-A-beta (pGluAB42). Recent studies confirm that pGluAB42 is a particular amyloid form that is highly synaptotoxic and plays a significant role in the development of AD.
Methods:This paper describes the design and methodology behind the VIVIAD-trial. The aim of this study is to evaluate varoglutamstat in a state-of-the-art phase 2b, placebo-controlled, double-blind, randomized clinical trial on safety and tolerability, efficacy on cognition, brain activity and AD biomarkers. In addition to its main purpose, the trial will explore potential associations between novel and established biomarkers and their individual and composite relation to disease characteristics.
Results: to be expected early 2023
Conclusion: This state of the art phase 2b study will yield important results for the field and the treatment of AD with a small molecule directed against pyroglutamate-A-beta.
Figure 1
Figure 2
Loading...
Posted 09 Mar, 2021
On 21 Mar, 2021
On 16 Mar, 2021
Received 16 Mar, 2021
Invitations sent on 03 Mar, 2021
On 03 Mar, 2021
On 03 Mar, 2021
On 03 Mar, 2021
On 03 Mar, 2021
Posted 09 Mar, 2021
On 21 Mar, 2021
On 16 Mar, 2021
Received 16 Mar, 2021
Invitations sent on 03 Mar, 2021
On 03 Mar, 2021
On 03 Mar, 2021
On 03 Mar, 2021
On 03 Mar, 2021
Background: Varoglutamstat (formerly PQ912) is a small molecule that inhibits the activity of the glutaminyl cyclase to reduce the level of pyroglutamate-A-beta (pGluAB42). Recent studies confirm that pGluAB42 is a particular amyloid form that is highly synaptotoxic and plays a significant role in the development of AD.
Methods:This paper describes the design and methodology behind the VIVIAD-trial. The aim of this study is to evaluate varoglutamstat in a state-of-the-art phase 2b, placebo-controlled, double-blind, randomized clinical trial on safety and tolerability, efficacy on cognition, brain activity and AD biomarkers. In addition to its main purpose, the trial will explore potential associations between novel and established biomarkers and their individual and composite relation to disease characteristics.
Results: to be expected early 2023
Conclusion: This state of the art phase 2b study will yield important results for the field and the treatment of AD with a small molecule directed against pyroglutamate-A-beta.
Figure 1
Figure 2
Loading...